Apartment Investment and Management Co vs Cytokinetics Inc — how do they compare? Apartment Investment and Management Co trades at $2.6 (market cap $376.16M), while Cytokinetics Inc trades at $76.51 (market cap $10.63B). The key difference: Cytokinetics Inc is far larger — about 28.3× Apartment Investment and Management Co's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Apartment Investment and Management Co nearer its low. Which is the better fit depends on your goals.
| AIV | CYTK | |
|---|---|---|
Market Cap | $376.16M | $10.63B |
Sector | Real Estate | Technology |
52-Week High | $7.93 | $87.26 |
52-Week Low | $2.59 | $34.31 |
Enterprise Value | $738.32M | $10.74B |
Signals from Pluang's Aura AI — not financial advice
AIV trades at $2.62, down 1.5% recently, with a bearish technical signal from moving averages. The company reported Q4 2025 EPS of $1.06, beating expectations, but revenue declined to $138.49M in 2025. Valuation ratios show a low P/B of 0.76, suggesting potential undervaluation, while a net income margin of 400.05% reflects significant one-time tax benefits. Cash flow improved with a net inflow of $234M in 2025.
Outlook is mixed: strong profitability metrics and a scheduled dividend in 2026 offer upside, but inconsistent earnings history and revenue volatility pose risks. Analyst consensus is cautious with 33% buy ratings. Investors should weigh the attractive valuation against operational challenges in the real estate sector.
CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.
The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.
Trailing returns across standard periods
Apartment Investment & Management Co is a self-managed real estate investment trust. It is focused on property development, redevelopment and various other value-creating investment strategies, targeting the U.S multifamily market. Its operating segments are Development and Redevelopment
Read more on AIV →Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →